In Risky Move, Alpharma Launches Generic Neurontin

Law360, New York (October 10, 2004, 12:00 AM EDT) -- In a risky move, Alpharma Inc. on Friday launched a generic version of Pfizer’s blockbuster epilepsy drug Neurontin without waiting for a court ruling on Pfizer's motion for a preliminary injunction.

Alpharma said the drug had already been shipped to wholesalers in 100 milligram, 300 mg and 400 mg doses, a step likely to sharply undercut Pfizer’s share of the $2.4 billion market for the drug.

Pfizer immediately struck back by launching its own generic version of the drug through its Greenstone Ltd. subsidiary.

“While Judge...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.